Summary:
A Blinded, randomized, parallel-group, Phase 3 study with aprocitentan in Subjects with Resistant Hypertension (RHT)
Qualified Participants Must:
Must be 18 or over
Been diagnosed with high blood pressure or hypertention
Take at least 3 or more blood pressure medications